All protocols
Weight Loss

Semaglutide Peptide Protocol & Dosing

Updated 1w ago 8 min read 156+ helpful Calculator
Validity Score

Validity Score

32 Speculative
Evidence 27
Community 70
Completeness 71
Actionability 80
Coverage 40
Penalty -18

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

Semaglutide is a long-acting GLP-1 receptor agonist studied for type-2 diabetes and obesity. The weekly obesity dose is 2.4 mg in the STEP program.

Evidence boundary

Human evidence exists for the studied indications.

Trial evidence

  • PMID 42686906 — Late-life semaglutide treatment slows ageing and extends lifespan in female mice.
  • PMID 42747817 — Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
  • PMID 42657770 — Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with Type 2 Diabetes.

Preparation and measurement

Reconstitution: 10 mg vial + 1 mL BAC = 10 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
PhaseDoseDraw / measureFrequencyWeekly total
Weeks 1–4250 mcg2.5 U (0.025 mL)Once weekly250 mcg/week
Weeks 5–8500 mcg5 U (0.05 mL)Once weekly500 mcg/week
Weeks 9–121 mg10 U (0.1 mL)Once weekly1 mg/week
Weeks 13–161.7 mg17 U (0.17 mL)Once weekly1.7 mg/week
Weeks 17+2.4 mg24 U (0.24 mL)Once weekly2.4 mg/week

Weeks 1–4

Dose
250 mcg
Draw / measure
2.5 U (0.025 mL)
Frequency
Once weekly
Weekly total
250 mcg/week

Weeks 5–8

Dose
500 mcg
Draw / measure
5 U (0.05 mL)
Frequency
Once weekly
Weekly total
500 mcg/week

Weeks 9–12

Dose
1 mg
Draw / measure
10 U (0.1 mL)
Frequency
Once weekly
Weekly total
1 mg/week

Weeks 13–16

Dose
1.7 mg
Draw / measure
17 U (0.17 mL)
Frequency
Once weekly
Weekly total
1.7 mg/week

Weeks 17+

Dose
2.4 mg
Draw / measure
24 U (0.24 mL)
Frequency
Once weekly
Weekly total
2.4 mg/week

Weekly totals apply only during the active phase.

Titration rules

  • 0.25 mg weekly is the cautious start.
  • 0.5 mg weekly is the next step.
  • 1 mg weekly is the middle step.
  • 1.7 mg weekly is the higher step.
  • 2.4 mg weekly is the usual maintenance dose in obesity trials.
  • Hold each step for 4 weeks before moving on.

Cycle length and breaks

Reassess after the main study window instead of inventing a break schedule.

What to monitor

  • Weight-loss response
  • HbA1c / glycemic response
  • Blood pressure and lipids
  • GI effects during escalation
  • Appetite suppression
  • Tolerability
  • Do not read this as an approved label.

Practical rules

  • Subcutaneous, once weekly.
  • Rotate injection sites.
  • Smaller meals and slower titration help with GI effects.
  • Keep protein and resistance training in the plan if lean mass matters.

Research coverage

Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on Semaglutide.

Was this protocol helpful?
Share via

Dosing references

Peptide dosage chart Peptide dose calculator Syringe mixability

Related protocols

Retatrutide Peptide Protocol & DosingTirzepatide Peptide Protocol & Dosing

Dosing Calculator

10 mg + 2 mL BAC · suggested 250 mcg
LIVE CALCULATIONvolume / concentration / draw
RP–CALC–01
DRAW AMOUNT5 units0.05 mL · U-100
Draw 5 units, equivalent to 0.05 milliliters.
Concentration5 mg/mL
Selected dose0.25 mg (250 mcg) = 5 units
Enter a desired amount in milligrams or micrograms.
05 Standard doses
06 Suggested doses Select a row
1 unit = 0.01 mL on a U-100 syringe. Values retain decimal precision; visual marks are not silently snapped.
07 cycle summary

Vials required for Cycle

Estimate how much material you need for a full cycle, including cycle length and the number of cycles you plan to run.

Cycle total —
Total required vials —
Total reconstitution —
Total BAC water —